Cargando…
Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management
BACKGROUND: Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (FTL1) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia. METHODS: A literature search was performed on Pubmed, for English-...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia University Libraries/Information Services
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795517/ https://www.ncbi.nlm.nih.gov/pubmed/27022507 http://dx.doi.org/10.7916/D8KK9BHF |
_version_ | 1782421616645373952 |
---|---|
author | Kumar, Niraj Rizek, Philippe Jog, Mandar |
author_facet | Kumar, Niraj Rizek, Philippe Jog, Mandar |
author_sort | Kumar, Niraj |
collection | PubMed |
description | BACKGROUND: Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (FTL1) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia. METHODS: A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF. RESULTS: There have been nine reported mutations worldwide in the FTL1 gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential diagnosis of NF to guide the clinician. DISCUSSION: NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success. |
format | Online Article Text |
id | pubmed-4795517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Columbia University Libraries/Information Services |
record_format | MEDLINE/PubMed |
spelling | pubmed-47955172016-03-28 Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management Kumar, Niraj Rizek, Philippe Jog, Mandar Tremor Other Hyperkinet Mov (N Y) Reviews BACKGROUND: Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (FTL1) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia. METHODS: A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF. RESULTS: There have been nine reported mutations worldwide in the FTL1 gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential diagnosis of NF to guide the clinician. DISCUSSION: NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success. Columbia University Libraries/Information Services 2016-03-08 /pmc/articles/PMC4795517/ /pubmed/27022507 http://dx.doi.org/10.7916/D8KK9BHF Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommerical–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed. |
spellingShingle | Reviews Kumar, Niraj Rizek, Philippe Jog, Mandar Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management |
title | Neuroferritinopathy: Pathophysiology, Presentation, Differential
Diagnoses and Management |
title_full | Neuroferritinopathy: Pathophysiology, Presentation, Differential
Diagnoses and Management |
title_fullStr | Neuroferritinopathy: Pathophysiology, Presentation, Differential
Diagnoses and Management |
title_full_unstemmed | Neuroferritinopathy: Pathophysiology, Presentation, Differential
Diagnoses and Management |
title_short | Neuroferritinopathy: Pathophysiology, Presentation, Differential
Diagnoses and Management |
title_sort | neuroferritinopathy: pathophysiology, presentation, differential
diagnoses and management |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795517/ https://www.ncbi.nlm.nih.gov/pubmed/27022507 http://dx.doi.org/10.7916/D8KK9BHF |
work_keys_str_mv | AT kumarniraj neuroferritinopathypathophysiologypresentationdifferentialdiagnosesandmanagement AT rizekphilippe neuroferritinopathypathophysiologypresentationdifferentialdiagnosesandmanagement AT jogmandar neuroferritinopathypathophysiologypresentationdifferentialdiagnosesandmanagement |